Functional interactions of varenicline and nicotine with nAChR subtypes implicated in cardiovascular control

Nicotine and Tobacco Research

Volumn 16, Issue 6, 2014, Pages 733-742

  Rollema, Hans ^a   Russ, Cristina ^b   Lee, Theodore C ^b   Hurst, Raymond S ^b   Bertrand, Daniel ^c  

^a Rollema Biomedical Consulting   (United States)

^b PFIZER INC   (United States)

^c HiQScreen   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BUNGAROTOXIN RECEPTOR; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA3ALPHA5BETA4; NICOTINIC RECEPTOR ALPHA3BETA4; UNCLASSIFIED DRUG; VARENICLINE; BENZAZEPINE DERIVATIVE; NICOTINIC AGENT; PROTEIN BINDING; QUINOXALINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CARDIOVASCULAR FUNCTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; ELECTROPHYSIOLOGY; HUMAN; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ANIMAL; METABOLISM; TOBACCO USE DISORDER; XENOPUS LAEVIS;

ANIMALS; BENZAZEPINES; HUMANS; NICOTINE; NICOTINIC AGONISTS; OOCYTES; PROTEIN BINDING; QUINOXALINES; RECEPTORS, NICOTINIC; TOBACCO USE DISORDER; XENOPUS LAEVIS;

EID: 84900032082     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntt208     Document Type: Article

References (43)

1. Aberger, K., Chitravanshi, V. C., & Sapru, H. N. (2001). Cardiovascular responses to microinjections of nicotine into the caudal ventrolateral medulla of the rat. Brain Research, 892, 138-146.
2. Balakumar, P., & Kaur, J. (2009). Is nicotine a key player or spectator in the induction and progression of cardiovascular disorders? Pharmacological Research, 60, 361-368. doi:10.1016/j.phrs.2009.06.005.
3. Benowitz, N. L. (2003). Cigarette smoking and cardiovascular disease: Pathophysiology and implications for treatment. Progress in Cardiovascular Diseases, 46, 91-111.
4. Benowitz, N. L., Hukkanen, J., & Jacob, P., III. (2009). Nicotine chemistry, metabolism, kinetics and biomarkers. Handbook of Experimental Pharmacology, 192, 29-60. doi:10.1007/978-3-540-69248-5_2.
5. Buccafusco, J. J., & Yang, X. (1993). Mechanism of the hypertensive response to central injection of nicotine in conscious rats. Brain Research Bulletin, 32, 35-41.
6. Bullen, C. (2008). Impact of tobacco smoking and smoking cessation on cardiovascular risk and disease. Expert Review of Cardiovascular Therapy, 6, 883-895. doi:10.1586/14779072.6.6.883.
7. Center for Drug Evaluation and Research. (2006). Pharmacology/toxicology review and evaluation [Approval package for: Application number NDA 21-928]. Retrieved from www.accessdata.fda.gov/drugsatfda_docs/nda/2006/ 021928_s000_Chantix_PharmR.pdf.
8. Chatterjee, S., Steensland, P., Simms, J. A., Holgate, J., Coe, J. W., Hurst, R. S., & Bartlett, S. E. (2011). Partial agonists of the alpha-3beta4 neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats. Neuropsychopharmacology, 36, 603-615. doi:10.1038/npp.2010.191.
9. D'Hoedt, D., & Bertrand, D. (2009). Nicotinic acetylcholine receptors: An overview on drug discovery. Expert Opinion on Therapeutic Targets, 13, 395-411. doi:10.1517/14728220902841045.
10. De Biasi, M. (2002). Nicotinic mechanisms in the autonomic control of organ systems. Journal of Neurobiology, 53, 568-579. doi:10.1002/neu.10145.
11. Faessel, H. M., Obach, R. S., Rollema, H., Ravva, P., Williams, K. E., & Burstein, A. H. (2010). A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. Clinical Pharmacokinetics, 49, 799-816. doi:10.2165/11537850-000000000-00000.
12. Fenster, C. P., Rains, M. F., Noerager, B., Quick, M. W., & Lester, R. A. (1997). Influence of subunit composition on desensitization of neuronal acetylcholine receptors at low concentrations of nicotine. Journal of Neuroscience, 17, 5747-5759.
13. Ford, C. L., & Zlabek, J. A. (2005). Nicotine replacement therapy and cardiovascular disease. Mayo Clinic Proceedings, 80, 652-656. doi:10.4065/80.5.652.
14. Gourlay, S. G., & Benowitz, N. L. (1997). Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clinical Pharmacology and Therapeutics, 62, 453-463. doi:10.1016/ S0009-9236(97)90124-7.
15. Hanna, S. T. (2006). Nicotine effect on cardiovascular system and ion channels. Journal of Cardiovascular Pharmacology, 47, 348-358. doi:10.1097/01.fjc.0000205984.13395.9e.
16. Harrison-Woolrych, M., Maggo, S., Tan, M., Savage, R., & Ashton, J. (2012). Cardiovascular events in patients taking varenicline: A case series from intensive postmarketing surveillance in New Zealand. Drug Safety, 35, 33-43. doi:10.2165/11597690-000000000-00000.
17. Hogg, R. C., Bandelier, F., Benoit, A., Dosch, R., & Bertrand, D. (2008). An automated system for intracellular and intranuclear injection. Journal of Neuroscience Methods, 169, 65-75. doi:10.1016/j.jneumeth.2007.11.028.
18. Hogg, R. C., & Bertrand, D. (2004). Nicotinic acetylcholine receptors as drug targets. Current Drug Targets. CNS and Neurological Disorders, 3, 123-130.
19. Iida, M., Iida, H., Takenaka, M., Tanabe, K., & Iwata, K. (2012). Preventive effect of varenicline on impairment of endothelial function in cerebral vessels induced by acute smoking in rats. Journal of Anesthesia, 26, 928-931. doi:10.1007/ s00540-012-1433-3.
20. Jutkiewicz, E. M., Rice, K. C., Carroll, F. I., & Woods, J. H. (2013, January 17). Patterns of nicotinic receptor antagonism II: Cardiovascular effects in rats. Drug and Alcohol Dependence, 131, 284-297. doi:10.1016/j. drugalcdep.2012.12.021.
21. Kuryatov, A., & Lindstrom, J. (2011). Expression of functional human alpha6beta2beta3 acetylcholine receptors in Xenopus laevis oocytes achieved through subunit chimeras and concatamers. Molecular Pharmacology, 79, 126-140. doi:10.1124/mol.110.066159.
22. Li, Y. F., Lacroix, C., & Freeling, J. (2010). Cytisine induces autonomic cardiovascular responses via activations of different nicotinic receptors. Autonomic Neuroscience, 154, 14-19. doi:10.1016/j.autneu.2009.09.023.
23. Mihalak, K. B., Carroll, F. I., & Luetje, C. W. (2006). Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Molecular Pharmacolgy, 70, 801-805. doi:10.1124/mol.106.025130.
24. Mills, E.J., Thorlund, K., Eapen, S., Wu, P., & Prochaska, J. J. (2013). Cardiovascular events associated with smoking cessation pharmacotherapies: A network meta-analysis. Circulation. doi 10.1161/CIRCULATIONAHA.113.003961.
25. Moore, C., Wang, Y., & Ramage, A. G. (2011). Nicotine's central cardiovascular actions: Receptor subtypes involved and their possible physiological role in anaesthetized rats. European Journal of Pharmacology, 668, 177-183. doi:10.1016/j.ejphar.2011.06.055.
26. Papke, R. L., Trocme-Thibierge, C., Guendisch, D., Al Rubaiy, S. A., & Bloom, S. A. (2011). Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists. Journal of Pharmacology and Experimental Therapeutics, 337, 367-379. doi:10.1124/ jpet.110.177485.
27. Pfizer Inc. (2013). Study to evaluate cardiac assessments following different treatments of smoking cessation medications in subjects with and without psychiatric disorders. (CATS). ClinicalTrials.gov Identifier: NCT01574703. Retrieved from http://clinicaltrials.gov/ct2/show/NCT0157 4703?term=Varenicline+AND+bupropion+AND+NRT+AN D+safety&rank=2.
28. Prochaska, J. J., & Hilton, J. F. (2012). Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: Systematic review and meta-analysis. British Medical Journal, 344, e2856. doi:10.1136/bmj. e2856.
29. Rigotti, N. A., Pipe, A. L., Benowitz, N. L., Arteaga, C., Garza, D., & Tonstad, S. (2010). Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: A randomized trial. Circulation, 121, 221-229. doi:10.1161/CIRCULATIONAHA.109.869008.
30. Rollema, H., Hajos, M., Seymour, P. A., Kozak, R., Majchrzak, M. J., Guanowsky, V., & Williams, K. E. (2009). Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochemical Pharmacology, 78, 813-824. doi:10.1016/j. bcp.2009.05.033.
31. Rollema, H., Shrikhande, A., Ward, K. M., Tingley, F. D., III, Coe, J. W., O'Neill, & B. T., Bertrand, D. (2010). Preclinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence. British Journal of Pharmacology, 160, 334-345. doi:10.1111/j.1476-5381.2010.00682.x.
32. Shimizu, T., Tanaka, K., Hasegawa, T., & Yokotani, K. (2011). Brain alpha4beta2 nicotinic acetylcholine receptors are involved in the secretion of noradrenaline and adrenaline from adrenal medulla in rats. European Journal of Pharmacology, 654, 241-248. doi:10.1016/j.ejphar.2010.12.034.
33. Singh, S., Loke, Y. K., Spangler, J. G., & Furberg, C. D. (2011). Risk of serious adverse cardiovascular events associated with varenicline: A systematic review and meta-analysis. Canadian Medical Association Journal, 183, 1359-1366. doi:10.1503/cmaj.110218.
34. Sobieraj, D. M., White, W. B., & Baker, W. L. (2013). Cardiovascular effects of pharmacologic therapies for smoking cessation. Journal of the American Society of Hypertension, 7, 61-67. doi:10.1016/j.jash.2012.11.003.
35. Sofuoglu, M., Herman, A. I., Mooney, M., & Waters, A. J. (2009). Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans. Psychopharmacology (Berl), 207, 153-162. doi:10.1007/ s00213-009-1643-z.
36. Stokes, C., & Papke, R.L. (2012). Use of an α3β4 nicotinic acetylcholine receptor subunit concatamer to characterize ganglionic receptor subtypes with specific subunit composition reveals species-specific pharmacologic properties. Neuropharmacology, 63, 538-546. doi:10.1016/j. neuropharm.2012.04.035.
37. Svanström, H., Pasternak, B., & Hviid, A. (2012). Use of varenicline for smoking cessation and risk of serious cardiovascular events: Nationwide cohort study. British Medical Journal, 345, e7176. doi:10.1136/bmj. e7176.
38. Tammimäki, A., Herder, P., Li, P., Esch, C., Laughlin, J. R., Akk, G., & Stitzel, J. A. (2012). Impact of human D398N single nucleotide polymorphism on intracellular calcium response mediated by alpha3beta4alpha5 nicotinic acetylcholine receptors. Neuropharmacology, 63, 1002-1011. doi:10.1016/j.neuropharm.2012.07.022.
39. Toh, S., Baker, M. A., Brown, J. S., Kornegay, C., & Platt, R. (2013). Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration's Mini-Sentinel Program. JAMA Internal Medicine, 173, 817-819. doi:10.1001/ jamainternmed.2013.3004.
40. Tseng, C. J., Appalsamy, M., Robertson, D., & Mosqueda-Garcia, R. (1993). Effects of nicotine on brain stem mechanisms of cardiovascular control. The Journal of Pharmacology and Experimental Therapeutics, 265, 1511-1518.
41. US Centers for Disease Control and Prevention. (2010). Cardiovascular diseases: Chapter 6. In How tobacco smoke causes disease: The biology and behavioral basis for smoking-attributable disease. A report of the Surgeon General. Atlanta, GA: Author. Retrieved from http://www.ncbi.nlm. nih.gov/books/NBK53017/pdf/TOC.pdf/.
42. US Food and Drug Administration. (2011). FDA Drug Safety Communication: Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patients with cardiovascular disease. Retrieved from www.fda.gov/Drugs/ Drugsafety/ucm259161.htm.
43. Ware, J. H., Vetrovec, G. W., Miller, A. B., Van Tosh, A., Gaffney, M., Yunis, C., & Borer, J. S. (2013). Cardiovascular safety of varenicline: Patient-level meta-analysis of randomized, blinded, placebo-controlled trials. American Journal of Therapeutics, 20, 235-246. doi:10.1097/ MJT.0b013e31828d455b.